Unicycive Therapeutics, Inc. (UNCY): Cash & Equivalents
$29.20M
As of 2025-12-31
$44.19M
As of 2026-06-30
n/m
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $29.20M | +11.7% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $26.14M | n/a | 2026-03-30, Balance as of period end |
| No annual figure between 2022-12-31 and 2024-12-31. | |||
| 2022-12-31 | $455.0K | -97.3% | 2023-03-31, Balance as of period end |
| 2021-12-31 | $16.58M | n/a | 2023-03-31, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | $29.20M | +11.7% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $30.79M | -54.1% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $46.82M | +22.1% |
| NextCure, Inc. (NXTC) | 2025-12-31 | $25.98M | -6.3% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $45.09M | +48.7% |
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | $0 | n/a |
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | $41.30M | -41.9% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $30.15M | -34.9% |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $48.00M | -34.2% |
Compare UNCY, VTGN, COYA, NXTC side by side · Screen every company in Pharmaceutical Preparations ↗